Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 369

Results For "MED"

6585 News Found

BASF Pharma Solutions excipient accepted into FDA Pilot Program
Drug Approval | December 06, 2022

BASF Pharma Solutions excipient accepted into FDA Pilot Program

Soluplus branded excipient play a critical role in enabling the drug development process for poorly soluble active pharmaceutical ingredients


JB Pharma reduces price of Azmarda by 50%
News | December 06, 2022

JB Pharma reduces price of Azmarda by 50%

Move to increase affordability and accessibility for heart failure patients across the country


ANSSI Wellness inaugurates its new spine clinic in Pune
Healthcare | December 06, 2022

ANSSI Wellness inaugurates its new spine clinic in Pune

Asia’s premier and USA-patented, ANSSI Wellness for spinal decompression was launched in Pune


ASG Eye Hospitals opens hospital in Vashi
Healthcare | December 06, 2022

ASG Eye Hospitals opens hospital in Vashi

The new eye hospital in Vashi is ASG’s second in the Mumbai Metropolitan Region (MMR) and the sixth in Maharashtra


Zydus receives final approval from USFDA for Estradiol Transdermal System
Drug Approval | December 05, 2022

Zydus receives final approval from USFDA for Estradiol Transdermal System

The drug will be manufactured at the group’s formulation manufacturing facility at Moraiya, Ahmedabad


Merck to present data from Its hematology portfolio ASH meeting
News | December 05, 2022

Merck to present data from Its hematology portfolio ASH meeting

Presentations include new data on investigational medicines – favezelimab (MK-4280), zilovertamab vedotin (MK-2140) and nemtabrutinib – as well as KEYTRUDA (pembrolizumab) in multiple blood cancers


Valneva and Pfizer report antibody persistence data for lyme disease vaccine candidate
News | December 05, 2022

Valneva and Pfizer report antibody persistence data for lyme disease vaccine candidate

Antibody levels remained above baseline six months after completion of a three-dose (Month 0-2-6) or a two-dose (Month 0-6) vaccination schedule


Jemperli RUBY phase III trial met its primary endpoint
Clinical Trials | December 05, 2022

Jemperli RUBY phase III trial met its primary endpoint

Results showed a statistically significant and clinically meaningful improvement in investigator-assessed progression-free survival


EMA accepts marketing authorisation application for momelotinib for the treatment of myelofibrosis
News | December 05, 2022

EMA accepts marketing authorisation application for momelotinib for the treatment of myelofibrosis

Application includes data from key phase III trials, including the pivotal MOMENTUM trial, which met all primary and key secondary efficacy endpoints


World’s first intra-nasal vaccine for COVID developed by India has got approval from CDSCO
News | December 02, 2022

World’s first intra-nasal vaccine for COVID developed by India has got approval from CDSCO

Phase-III trials were conducted for safety, and immunogenicity in around 3,100 subjects, in 14 trial sites across India (supported by BIRAC)